Search hospitals

>

Massachusetts

>

Boston

Boston Children's Hospital

Claim this profile

Boston, Massachusetts 02115

Global Leader in Cystic Fibrosis

Global Leader in Congenital Heart Diseases

Conducts research for Sickle Cell Disease

Conducts research for Epilepsy

Conducts research for Congenital Heart Disease

1223 reported clinical trials

124 medical researchers

Photo of Boston Children's Hospital in BostonPhoto of Boston Children's Hospital in BostonPhoto of Boston Children's Hospital in Boston

Summary

Boston Children's Hospital is a medical facility located in Boston, Massachusetts. This center is recognized for care of Cystic Fibrosis, Congenital Heart Diseases, Sickle Cell Disease, Epilepsy, Congenital Heart Disease and other specialties. Boston Children's Hospital is involved with conducting 1,223 clinical trials across 1,622 conditions. There are 124 research doctors associated with this hospital, such as Susan Chi, MD, Dr. David Brown, Katherine A. Janeway, and Steven G. DuBois, MD, MS.

Area of expertise

1

Cystic Fibrosis

Global Leader

Boston Children's Hospital has run 99 trials for Cystic Fibrosis. Some of their research focus areas include:

CFTR positive
CFTR
CF-causing mutations positive
2

Congenital Heart Diseases

Global Leader

Boston Children's Hospital has run 58 trials for Congenital Heart Diseases.

Top PIs

Clinical Trials running at Boston Children's Hospital

Crohn's Disease

Deletion Syndrome

Duplication Syndrome

Rett Syndrome

Epilepsy

Ulcerative Colitis

Intellectual Disability

Inflammatory Bowel Disease

Genetic Disorders

Bronchopulmonary Dysplasia

Image of trial facility.

Anti-TNF Therapy

for Crohn's Disease in Children

Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause of CD is not certain it is thought that the immune system located in the intestine reacts abnormally to the large number of bacteria contained there. The investigators think that diet, exposure to antibiotics early in life, and having a family history of CD puts people at increased risk for developing CD. In order to decrease the inflammation doctors use what is called biologic therapy with anti-TNF molecules that can be given through an intravenous or shots. TNF is a chemical made by white blood cells that is involved in inflammation. When this type of treatment is given early after diagnosis it is more effective than when it is given later. The investigators have learned that it is important to give the optimum (ideal) amount of this medicine guided by certain blood tests. The investigators also know that not everyone responds to this therapy but do not understand the reasons for this variability between people. The CAMEO study has been started to help understand what factors are important in determining whether a child with CD completely heals the inflammation after anti-TNF therapy. The investigators will do that by measuring certain markers of inflammation in the blood and stool and by looking at a person's genes (DNA) and how inflammation is controlled in the intestine. These inflammation tests will be done before, during, and after one year of anti-TNF therapy. The investigators will determine how much healing has taken place by comparing the results of the colonoscopy and a special type of MRI that are both done before anti-TNF and then again one year later. The goal in treating CD is to heal both the lining and the wall of the intestine. Children ages 6-17 years who are thought to have CD and are about to undergo their diagnostic colonoscopy are eligible to be enrolled. If they are found to indeed have CD and start an anti-TNF medicine within 6 months they can continue in the study. There are no increased risks of participating in this study beyond those normally associated with having CD and its treatment. By better understanding why the bowel does or does not heal, doctors will be better able to provide personalized care.

Recruiting

3 awards

Phase 4

7 criteria

Image of trial facility.

Vedolizumab

for Ulcerative Colitis and Crohn's Disease

The study is an extension of two parent studies (MLN0002-3024 \[NCT04779307\] and MLN0002-3025 \[NCT04779320\]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.

Recruiting

3 awards

Phase 3

Image of trial facility.

Guselkumab

for Pediatric Crohn's Disease

This trial tests guselkumab, an anti-inflammatory medication, on children with Crohn's Disease who initially responded well to it. The goal is to see if the benefits last over several months by reducing immune system activity. Guselkumab has shown effectiveness in treating moderate-to-severe psoriasis and psoriatic arthritis.

Recruiting

2 awards

Phase 3

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Boston Children's Hospital?

Where is Boston Children's Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does Boston Children's Hospital accept?

What awards or recognition has Boston Children's Hospital received?